Biotech Values

[ghmm]

I asked IJ about it (either here or on SI) and he seemed reluctant to to go with it. I guess safety will be the big concern with Campath in MS and may prevent it from becoming a front-line therapy. I wonder if at some efficacy level some MS patients would try it ahead of other therapies despite the risks? On an analyst day (maybe a couple years ago) Henri claimed that monitoring could help with the risks but his creditability is suspect (especially these days).

EDIT:

Here is the old nature article on it if anyone is interested (I don't think you need to register but if you do its free since I never paid).
http://www.nature.com/nbt/journal/v27/n1/full/nbt0109-6.html